(RTTNews) - Asian stocks ended mixed on Monday as Middle East tensions persisted, hawkish signals from Federal Reserve policymakers bolstered the case for another Fed rate hike this year, and new data showed China's industrial profit growth slowed further in August.
Oil prices
(RTTNews) - Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company, released its second-quarter 2026 financial results on Monday and provided corporate updates for the quarter.
Key PointsAlthough the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have soared under President Trump, it’s becoming increasingly difficult to sweep energy inflation under the rug.
(RTTNews) - Clinical-stage biotechnology company OSE Immunotherapeutics (OSE) reported a cash position of €11.1 million as of June 30, 2026, while highlighting progress across its oncology and immunology pipeline and reaffirming funding expected to support operations through Dece
(RTTNews) - NeuroSense Therapeutics Ltd. (NRSN), a late-stage clinical biotechnology company focused on treatments for neurodegenerative diseases, provided a business update and first-half 2026 financial results reflecting a narrower net loss.
The S&P 500 Index ($SPX ) (SPY ) closed up by +0.51% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.93%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. December E-mini S&P futures (ESZ26 ) rose +0.47%, and December E-mini...
(RTTNews) - Burford Capital Limited (BUR, BUR.L) issued a statement regarding the verdict, in a case captioned Taction Technology, Inc. v. Apple Inc., which represents one of the largest patent verdicts in U.S. history. On September 25, a jury in a case in which Burford has a fin
(RTTNews) - Agfa-Gevaert (AGFB.BR), an imaging technology company, on Monday announced that it has entered into a definitive agreement with Electronics for Imaging to combine Agfa's Digital Printing Solutions business with EFI.
(RTTNews) - Kodiak Sciences Inc. (KOD), a pre-commercial, retina-focused biotechnology company, is expected to report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in patients with wet age-relat
People (PPLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.